Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
about
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma.Second-line systemic treatment for advanced cholangiocarcinomaCurative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.Outcomes of endoscopic pyloric stenting in malignant gastric outlet obstruction: a retrospective studyBRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.Improvement of prognosis for unresectable biliary tract cancer.A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.Current status of chemotherapy for the treatment of advanced biliary tract cancer.Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.Second-line chemotherapy in advanced biliary cancer: a systematic review.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.New Horizons for Precision Medicine in Biliary Tract Cancers.Locoregional Therapies of Cholangiocarcinoma.Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case reportA phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin.A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
P2860
Q33402129-35CFA2B9-6C64-4B2B-88B0-D32ACF9DB897Q33415304-609E9362-B1F4-47A8-83DB-5DA42379EB50Q33419175-2E1067DC-FABE-4F2C-BEF9-AFAFD4ED6BA8Q33420378-B9B5D217-16FC-4F40-BD6B-6A3A583D1240Q33844564-9D67E0EF-4A01-4A80-8644-03E98B256B1AQ34484299-484EC8B2-2DFC-4CDE-A9BE-3BAC6846C48CQ34484514-DDE64314-E9A0-49CD-9A88-00D2F59D83FFQ34839721-C6D43085-90EB-46DE-BC20-909BEC1682FBQ35674192-19EFBAFA-20E1-4F0C-8434-0025DF3BBEFFQ36525533-9AFF2263-AB57-4B38-A5C1-086FB88E945AQ36795363-ED300E13-14EE-4F08-B1A8-255635AE8ED5Q37138732-471771D6-85F7-473A-BC5F-D1D06F12A7CEQ37728873-2307FCE7-3F8A-4AF5-AAC6-1E4E8E5AB916Q38207456-039BBB1C-549F-4270-9364-BD9F8362EC21Q38577917-F42CB6AB-0A3E-429D-B926-54AF4CBCC91BQ38619219-E9613910-ACFD-4381-ACA8-5BB386E4052AQ38947234-FC6015D6-3A19-4E29-BC87-F8D1221E0DAAQ40860251-43D7D28E-A90E-43E9-BB9E-A5FD4D5A9BF4Q41389333-AA97D90E-74DE-4683-A4D4-153AF297CB7CQ45903506-E1A3F4D2-2FE7-496C-982E-7C250A28BDBDQ46974800-93851FCB-E545-49EB-A359-4EA572D20DD2Q48126896-573B52DE-A0AA-4ADB-8351-3C64B9FF224BQ48333251-C6623BCC-12BC-450B-BEAA-1393F6A1D6DEQ50575839-16BB47E8-7933-4B0F-AEB3-B56FAB12AE39Q50609881-6390CC5E-4855-412D-B0AE-92E1913819D2Q53579614-90EFFF62-646E-428B-8863-4806E395665A
P2860
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Multicenter phase II study of ...... cer refractory to gemcitabine.
@en
Multicenter phase II study of ...... cer refractory to gemcitabine.
@nl
type
label
Multicenter phase II study of ...... cer refractory to gemcitabine.
@en
Multicenter phase II study of ...... cer refractory to gemcitabine.
@nl
prefLabel
Multicenter phase II study of ...... cer refractory to gemcitabine.
@en
Multicenter phase II study of ...... cer refractory to gemcitabine.
@nl
P2093
P2860
P50
P1476
Multicenter phase II study of ...... ncer refractory to gemcitabine
@en
P2093
Hirofumi Kogure
Hiroshi Yagioka
Hiroyuki Isayama
Keisuke Yamamoto
Kenji Hirano
Masao Omata
Minoru Tada
Nobuo Toda
Osamu Togawa
Saburo Matsubara
P2860
P2888
P304
P356
10.1007/S10637-010-9553-9
P577
2010-10-06T00:00:00Z